Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
NEW YORK, Nov. 6 /PRNewswire/ -- QED International Associates Inc., administrator for the HealthShares(TM) Exchange-Traded Funds, a series of 20 underlying fund portfolios, today announced that...
Siemens to secure leadership position in laboratory diagnostics market ERLANGEN, Germany, Oct. 25 /PRNewswire-FirstCall/ -- Siemens today received approval by the European Commission for the...
MUNICH, Germany, Sept. 27 /PRNewswire-FirstCall/ -- Siemens has extended the expiration date for the cash tender offer for all outstanding shares of Dade Behring Holdings, Inc. (NASDAQ:DADE) to...
NEW YORK, Sept. 18 /PRNewswire-FirstCall/ -- Siemens Corporation, a wholly owned subsidiary of Siemens AG (NYSE:SI), announced today that the statutory waiting period under the Hart-Scott-Rodino...
NEW YORK, Sept. 5 /PRNewswire-FirstCall/ -- Belfast Merger Co., a wholly owned subsidiary of Siemens Corporation, announced today that it has extended the expiration date for its cash tender...
Dade Behring Holdings, Inc. (NASDAQ:DADE) today reported second quarter earnings per share of $0.61, an increase of 18 cents or 42 percent over the same quarter in 2006, and...
Dade Behring Holdings, Inc. (NASDAQ:DADE), the world's largest company solely dedicated to clinical diagnostics, announced today that the company's board of directors has...
Dade Behring Inc. (NASDAQ:DADE) and Roche Diagnostics announced today that they have granted DiaSorin certain rights related to the development, marketing and manufacturing of...
Dade Behring Inc. (NASDAQ:DADE), the world's largest company solely dedicated to clinical diagnostics, and MedAssets Supply Chain Systems, one of the leading health care group...
Dade Behring Inc. (NASDAQ:DADE), the world's largest company solely dedicated to clinical diagnostics, today announced the introduction of several enhancements to the Company's...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
